Do Kim
Stock Analyst at Piper Sandler
(2.02)
# 3,083
Out of 5,005 analysts
92
Total ratings
44.93%
Success rate
3.01%
Average return
Main Sectors:
Stocks Rated by Do Kim
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $62 → $63 | $69.15 | -8.89% | 18 | Feb 22, 2024 | |
| TVTX Travere Therapeutics | Maintains: Overweight | $42 → $46 | $24.64 | +86.69% | 6 | Feb 21, 2023 | |
| VRTX Vertex Pharmaceuticals | Maintains: Neutral | $296 | $403.30 | -26.61% | 13 | Feb 8, 2023 | |
| GILD Gilead Sciences | Maintains: Overweight | $111 → $112 | $112.69 | -0.61% | 7 | Feb 3, 2023 | |
| SDGR Schrödinger | Maintains: Overweight | $86 → $87 | $20.59 | +322.54% | 5 | Jan 19, 2023 | |
| CDXS Codexis | Maintains: Overweight | $22 → $23 | $2.54 | +805.51% | 2 | Jan 19, 2023 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $10 → $20 | $28.54 | -29.92% | 3 | Aug 17, 2022 | |
| REPL Replimune Group | Maintains: Overweight | $44 → $43 | $4.73 | +809.09% | 2 | Aug 16, 2022 | |
| EXEL Exelixis | Maintains: Overweight | $30 → $32 | $40.09 | -20.18% | 1 | Jul 26, 2022 | |
| ABCL AbCellera Biologics | Maintains: Overweight | $21 → $22 | $5.90 | +272.88% | 4 | Jul 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $19 | $37.47 | -49.29% | 3 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $3.71 | +331.27% | 1 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $185 | $456.35 | -59.46% | 14 | Jan 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $900 | $4.17 | +21,482.73% | 1 | Dec 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $35 | $68.98 | -49.26% | 11 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7 → $20 | $1.21 | +1,552.89% | 1 | Mar 6, 2018 |
Ionis Pharmaceuticals
Feb 22, 2024
Maintains: Overweight
Price Target: $62 → $63
Current: $69.15
Upside: -8.89%
Travere Therapeutics
Feb 21, 2023
Maintains: Overweight
Price Target: $42 → $46
Current: $24.64
Upside: +86.69%
Vertex Pharmaceuticals
Feb 8, 2023
Maintains: Neutral
Price Target: $296
Current: $403.30
Upside: -26.61%
Gilead Sciences
Feb 3, 2023
Maintains: Overweight
Price Target: $111 → $112
Current: $112.69
Upside: -0.61%
Schrödinger
Jan 19, 2023
Maintains: Overweight
Price Target: $86 → $87
Current: $20.59
Upside: +322.54%
Codexis
Jan 19, 2023
Maintains: Overweight
Price Target: $22 → $23
Current: $2.54
Upside: +805.51%
Rigel Pharmaceuticals
Aug 17, 2022
Maintains: Neutral
Price Target: $10 → $20
Current: $28.54
Upside: -29.92%
Replimune Group
Aug 16, 2022
Maintains: Overweight
Price Target: $44 → $43
Current: $4.73
Upside: +809.09%
Exelixis
Jul 26, 2022
Maintains: Overweight
Price Target: $30 → $32
Current: $40.09
Upside: -20.18%
AbCellera Biologics
Jul 26, 2022
Maintains: Overweight
Price Target: $21 → $22
Current: $5.90
Upside: +272.88%
Jun 23, 2022
Maintains: Overweight
Price Target: $28 → $19
Current: $37.47
Upside: -49.29%
Mar 8, 2021
Initiates: Outperform
Price Target: $16
Current: $3.71
Upside: +331.27%
Jan 25, 2021
Downgrades: Market Perform
Price Target: $185
Current: $456.35
Upside: -59.46%
Dec 18, 2020
Initiates: Outperform
Price Target: $900
Current: $4.17
Upside: +21,482.73%
May 12, 2020
Maintains: Outperform
Price Target: $27 → $35
Current: $68.98
Upside: -49.26%
Mar 6, 2018
Maintains: Outperform
Price Target: $7 → $20
Current: $1.21
Upside: +1,552.89%